Market Research Blog

The global Varicella Zoster Infection Treatment Market in 2020 is estimated for more than US$ 1.5 Bn and expected to reach a value of US$ 2.0 Bn by 2028 with a significant CAGR of 4.1%. As per Future Market Insights’ projections, in 2022, the acyclovir holds a substantial share of over 55.7% in the overall varicella zoster infection treatment market.

Human alphaherpesvirus 3, also known as Varicella Zoster virus (VZV) is one of the many herpesviruses that is known to infect humans.  It is also the one causing infectious diseases like chicken pox (which is mostly common among children and teens) and herpes zoster (shingles) (mostly affecting adults but rarely in children).  The growing incidence of herpes zoster (shingles) infection among the children’s and the elderly and the rising demand towards the treatment of the infection is aiding the growth of the market.

Request a Sample Report with Table of Contents and Figures: https://www.futuremarketinsights.com/reports/sample/rep-gb-6466

For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are Valeant Pharmaceuticals International Inc., Teva Pharmaceutical Industries Ltd, Pfizer Inc., Mylan N.V., Abbott Laboratories, GlaxoSmithKline Plc., and Dr. Reddy’s Laboratories Ltd., among others.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market 

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well. These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Our advisory services are aimed at helping you with specific, customised insights that are relevant to your specific challenges. Let us know about your challenges and our trusted advisors will connect with you: https://www.futuremarketinsights.com/askus/rep-gb-6466

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.

Table Of Content

1. Executive Summary

2. Market Introduction

3. Varicella Zoster Infection Treatment Market Opportunity Analysis 

4. Market Background

5. Global Economic Outlook

6. Key Inclusions

Ask for TOC @ https://www.futuremarketinsights.com/toc/rep-gb-6466

Contact Us:                                                      

Future Market Insights
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

The global Herpes Labialis Treatment Market is expected to register a CAGR of nearly 4.7% over the forecast period (2022-2028) owing to increasing cases of recurrent herpes simplex infections. The herpes labialis treatment market recorded sales worth U.S. $ 1.03 Bn in the year 2021 and is expected to reach U.S. $ 1.42 Bn by the year 2028, according to the Future Market Insights (FMI) study.

The herpes labialis treatment market accounts for nearly 2% of the market share by value of the overall Antiviral Drugs Market, which was valued at nearly US$ 52.7 Bn in the year 2020. The herpes labialis treatment market experienced an increase in the demand in the past few year owing to the rising prevalence of herpes labialis infections around the world. Herpes labialis is caused by herpes simplex virus (HSV), which primarily affects the lips and are alternatively called as cold sores. According to the World Health Organization’s 2020 statistics, approximately 3.7 million people suffered from HSV 1 infection globally.

To know key findings Request Sample Report @: https://www.futuremarketinsights.com/reports/sample/rep-gb-6461

North America to Maintain Leading Regional Market Position

Supported by strong presence of a few of the key industry players, North America’s herpes labialis treatment market is expected to continue its dominance throughout the forecast period. While this region registered over 35% value share, Western Europe recorded a share of over 20% in 2017. North American region is presumed to exceed the revenues worth US$ 450 Mn by the end of 2027, observing a declining CAGR of 3.9%. Although the US will lead the North American region, Future Market Insights projects that Canada will witness higher adoption of herpes labialis treatment in the assessment period.

On the flipside, emerging regional markets such as APEJ, MEA, Eastern Europe, and Latin America will see rapid growth in the forecast period. APEJ is identified to be the fastest growing market at a promising CAGR of 5.7%, followed by MEA, predicted to grow at 5.3% CAGR over 2017-2027. Strengthening efforts and accelerating investments in the examination of the clinical efficacy of drugs, increasing expenditure on R&D infrastructure, growing consumer awareness, and development of advanced, cost-effective treatment options at a rapid pace, will collectively lift the market in emerging countries up. Moreover, lenient FDI policies that govern the pharmaceuticals industry in developing economies prompt at the inflow of a series of opportunities for drug companies to explore these regional markets in near future.

Request for Report customization @: https://www.futuremarketinsights.com/customization-available/rep-gb-6461

Key Market Players

Some of the leading players competing in the global herpes labialis treatment market include Novartis AG, Valeant Pharmaceuticals International Inc., Pfizer Inc., Abbott Laboratories, Mylan NV, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and GlaxoSmithKline plc. A majority of key players are directing their efforts towards extension of existing product portfolio, while others are focusing on strategic mergers and acquisitions in order to grab larger market shares in terms of revenue. Many top brands are looking forward to capitalize on growing opportunities in emerging regional markets.

The global zika virus testing market experienced a moderate incline, experiencing a CAGR of just above 2% between 2017 and 2020, being valued at a little over US$ 4 billion, as per ESOMAR-certified firm Future Market Insights (FMI) latest report on the landscape. Growth was majorly underpinned by the introduction of numerous point-of-care powerful testing approaches to facilitate timely detection of the virus.

According to FMI’s analysis, clinicians have been exhibiting a high preference towards enzyme linked immunosorbent assay (ELISA) tests. Compared to other immunoassay methods, ELISA tests are more accurate, are considered highly sensitive, specific and compare favorably with other methods used to detect substances in the body, such as radioimmune assay (RIA) tests.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/REP-GB-2913

Prominent players are experiencing immense growth opportunities across tropical regions, attributed to the high concentration rate of the zika virus across such regions as the Caribbean, Central America, Africa and the Asian sub-continent. Players such as EUROIMMUN have emerged at the forefront, being the first diagnostics company to provide a testing approach to detect the zika virus. Its product lines include the Anti-Zika Virus ELISA (IgA or IgG or IgM or IgAM) fully automatable test and the IIFT Arbovirus Fever Mosaic 2 (IgG or IgM) test.

Key Takeaways from FMI’s Zika Virus Testing Market Study

• By test type, ELISA-based zika virus testing surpassed US$ 4 billion until 2020
• By end-user, private commercial laboratories to remain primary point of contact for availing zika virus testing
• Multiple regulatory approvals for various testing approaches by the FDA to bolster US zika virus testing market growth
• Brazil to attract major zika virus testing providers amid increasing governmental initiatives to contain its spread
• Growing focus on pregnant women’s health to accelerate testing volumes in Puerto Rico
• UK to experience limited uptake amid the non-notifiable nature of the disease due to limited outbreaks

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-2913

Competitive Landscape

Prominent zika virus testing manufacturers are reliant on offering advanced testing approaches in order to yield quicker results so as to facilitate timely treatment. Besides, key research laboratories and organizations also emphasize on expanding their testing capabilities by virtue of strategic acquisition and collaboration agreements.

In 2017, the US FDA issued an Emergency Use Authorization (EUA) to authorize the RealStar^® Zika Virus RT-PCR Kit for the in vitro qualitative detection of Zika virus with specified instruments. This test is offered by Altona Diagnostics GmbH, and tests presence of the virus in human serum, EDTA plasma and/or urine.

Similarly, ARUP Laboratories offers both serology and RT-PCR tests for detecting the zika virus. The former is called the Zika Virus IgM Antibody Capture (MAC) based on the ELISA technique. In the latter case, the test is conducted by collecting patients’ blood or urine samples.

Why Future Market Insights?

•   Comprehensive analysis on evolving purchase pattern across different geographies
•   Detailed insights of market segments and sub-segments for historical as well as forecast period
•   A competitive analysis of prominent players and emerging players in the keyword market
•   Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Buy Now Report@ https://www.futuremarketinsights.com/checkout/2913

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

According to a newly published Future Market Insights report, the global rare neurological disease treatment market will exhibit a splendid expansion throughout the forecast period (2017-2026). Revenues from the market are envisaged to exceed US$ 12,000 Mn by 2026-end.

Declining blockbuster drugs are leading pharmaceutical industries to keenly investigate new avenues of research and development. Several drug manufacturers, incentivized by Orphan Drug Act, are developing new drug formulations pertaining to the treatment of rare diseases, in a bid to introduce new treatment options to the market. This has further influenced the development of drugs for treatment of rare neurological disorders. Regulatory advantages including breakthrough designations, reduced fees & tax incentives, and longer market exclusivity, are encouraging investments in the R&D of drugs apropos to rare neurological diseases.

Download Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-6445

A new report of Future Market Insights offers forecast and analysis on the rare neurological disease treatment market on a global level. The report delivers actual data related to the market for the historical period (2012-2016) along with an estimated intelligence on the market for the forecast period (2017-2026). The information is presented in terms of value (US$ Mn). Macroeconomic indicators coupled with an outlook on the rare neurological disease treatment demand pattern around the world have also been encompassed by the report. The report further imparts key drivers and restraints for the global rare neurological disease treatment market, and their impact on regional segments included over the forecast period.

Report Structure

The executive summary chapter, which initiates the report, offers key market dynamics and numbers associated with the global rare neurological disease treatment market, along with key research findings related to the market segments comprised. The market numbers included in this chapter are a blend of compound annual growth rates, market shares, revenues, and volume sales.

A concise introduction to the rare neurological disease treatment market is offered in the chapter succeeding the executive summary, along with a formal definition of “rare neurological disease treatment”. Elaboration of the market dynamics that include future prospects, growth limitations & drivers, and trends has been delivered in the chapters subsequent to the overview. These chapters also inundate insights apropos to bottom line of enterprises in detail, along with the fiscal stimulus and the global economy.

Market Taxonomy

Region

• North America
• Latin America
• Europe
• Japan
• APEJ
• MEA

Indication

• Alzheimer’s Disease
• Narcolepsy
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Other Indications

Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-6445

Drug Type

• Biologics
• Organic Compounds

Mode of Administration

• Injectables
• Oral
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Competition Landscape

A complete package of intelligence on leading participants supporting expansion of the global rare neurological disease treatment market has been offered in the concluding chapter of this analytical research report. This chapter elucidates the competition landscape of the global market for rare neurological disease treatment, providing information on key strategy implementations of the market players, their product overview, key development, company overview, and key financials. A SWOT analysis on each market players has been provided in this chapter of the report.

Buy Report Now @ https://www.futuremarketinsights.com/checkout/6445

FMI’s report identifies and tracks key players influencing expansion of the rare neurological disease treatment market that include EMD Serono, Inc., Jazz Pharmaceuticals, Teva Pharmaceutical Industries Limited, Johnson & Johnson, Sanofi, Medtronic Plc, Bayer Aktiengesellschaft, and Novartis AG.

The geographical spread of the market players included, along with their future growth plans, intended mergers & acquisitions, overall revenues, and market shares are elaborated in detail in this chapter. The report has employed an intensity map for portraying key market players located across geographies.

Research Methodology

Credibility of researched statistics & data is backed by a unique research methodology used by analysts at FMI, ensuring high accuracy. This research report on global rare neurological disease treatment market can assist readers in acquiring detailed insights on several aspects that govern the market across the regional segments contained in the report. The report readers can use slated strategies to tap the vital revenue pockets, thereby gaining benefits over intensifying competition prevailing in the market. Intelligence presented in this report has been scrutinized & monitored thoroughly by FMI’s industry experts. The figures and numbers offered by the report are validated by the analysts for facilitating strategic decision making for market players.

Significant findings from report show that the global rare inflammatory disease treatment market will increase at an assessed 4.4% CAGR during the forecast period, 2017-2026. The report also anticipates that by 2026-end, rare inflammatory disease treatment worth nearly US$ 15,960.8Mn will be witnessed across the globe.

With mounting instances of genetic diseases, demand for therapeutic measures have witnessed a hike, as no effective procedures exist that provide effective treatment of genetic or rare inflammatory diseases.  Chromosomal changes primarily influence prevalence of these diseases. In a bid to curtail the disease prevalence, several pharmaceutical industries have been taking efforts to make advancements in relevant drugs as well as therapeutic methods. For example, new treatment options are being developed by researchers for geriatric and pediatric patients suffering from Still’s disease, which is a rare disease linked with the inflammation of joints.

To Get Sample Copy of Report visit @ https://www.futuremarketinsights.com/reports/sample/REP-GB-6428

Doctors are stepping up their efforts by creating awareness among the patients with regard to benefits of anti-inflammatory drugs, which have been deemed effective in the prevention and control of rare inflammatory diseases. Currently, there is rapid increase in the demand for authorized effective treatments of the rare inflammatory diseases. The OOPD (Office of Orphan Products Development) has been offering incentives to drug companies, supporting the development of treatment methods for these diseases. National Institutes of Health (NIH) are providing immense support for improving patients’ health, by focusing mainly on the development of new treatment methods. Collaborative projects are being initiated by NIH in order to examine the common causes and effects of related diseases.

Increasing Inflammatory & Autoimmune Diseases to Create Opportunities for New Therapies

Several group of scientists have associated cytokine IL-23 with treatment of inflammatory and autoimmune diseases, which in turn is creating new ways of development for therapies. Researchers have identified a fundamental molecular mechanism essential to inflammatory and autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and psoriasis. The action of pro-inflammatory cytokine IL-23, depends on the organizational stimulation of its receptor, namely IL-23R.

Moreover, the occurrence of inflammatory and autoimmune diseases is increasing on a rapid pace. Globally, an approximate number of 125 million populace are affected by psoriasis and around 100 million by rheumatoid arthritis annually. The presence of inflammatory bowel infections such as ulcerative colitis and Crohn’s disease is increasing at an alarming rate in formerly unaffected fragments of the world.

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-6428

Key Takeaways from Rare Inflammatory Disease Treatment Market Report for Estimated Period, 2017-2026

• In terms of revenue, North America will remain the largest market for rare inflammatory disease treatment market, closely followed by Europe. Nearly half value share of the market is held by rare inflammatory disease treatment sales in North America and Europe collectively. APEJ will also bolt onto a largest market revenue share, by registering a relatively faster expansion than Europe in the market through 2026.
• On the basis of indication, ulcerative colitis are likely to remain considerably larger than that of the other segments.
• The lion’s share in the global market for rare inflammatory disease treatment is contributed by biologics segment.
• Oral care & Hospital Pharmacies will observe fastest growth during the forecast period.

Key market players outlined by the report is inclusive of Pfizer, Inc., Allergan Plc, Valeant, Johnson & Johnson, Questcor Pharmaceuticals, Inc., Novartis AG, Abbvie, Abbott Laboratories, Regeneron Pharmaceuticals, and Swedish Orphan Biovitrum AB.

Why Future Market Insights?

•   Comprehensive analysis on evolving purchase pattern across different geographies
•   Detailed insights of market segments and sub-segments for historical as well as forecast period
•   A competitive analysis of prominent players and emerging players in the keyword market
•   Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

Buy Now Report@ https://www.futuremarketinsights.com/checkout/6428 

About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

A dental handpiece is an instrument used to hold dental burs, disks, or cups in order to perform tooth removal or to perform cleaning and polishing of teeth or restorative material. The instrument is available in two modalities that includes air driven and electrically driven handpieces. It is powered by either electric motor or air turbines.

This Wearable Blood Pressure Monitor market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Wearable Blood Pressure Monitor market.

Wearable blood pressure monitors are smaller than the traditional blood pressure devices. Most wearable blood pressure monitors are digital and the new smart wearable blood pressure monitors are operated through apps. Wearable blood pressure monitors are available in three basic forms, which are wrist blood pressure monitor, upper arm blood pressure monitor, finger blood pressure monitor. Among all types of wearable blood pressure monitors, the wrist wearable blood pressure monitors are of particular interest due to the easy use and non-bulky look and design. With the advancement in technology the wrist based wearable blood pressure monitors are becoming sleeker and slim such as the recently launched Omron’s Heart Guide. The device looks like a smart watch, and also has the features of a smart watch. The Heart Guide is a step towards in the inclusion of blood pressure monitoring through a fitness tracker. Further advancement in technology for wearable blood pressure monitors is expected to drive the growth and adoption of wearable blood pressure monitor market globally, throughout the forecast period.

Download FREE Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9401

Wearable blood pressure monitor Market: Drivers and Restraints

Increasing prevalence of hypertension, increase in healthcare spending and rise in adoption of wireless and wearable technology are some of the factors that drive the growth of wearable blood pressure monitors. Others factors such as increase in ageing population and rise in cardiovascular disorders also drive the growth of wearable blood pressure monitors. However, increased cost of wearable blood pressure monitors, lack of precision when compared to conventional devices and compatibility issues with other devices are some of the factors that may hinder the growth of the wearable blood pressure monitor market.

Wearable blood pressure monitor Market: Overview

Increase in hypertension population is primarily driven by changes in lifestyle and adoption of sedentary lifestyle. The increase in fast pace lifestyle has moved patients from regular visit to doctor to opting the use of compatible, easy to use wearable blood pressure monitors. Wearable blood pressure monitors are currently still being developed from wireless upper arm monitors to bulky wrist monitors to recently FDA approved watch type of blood pressure monitors. With the advancement in technology the adoption of such wearable blood pressure monitors is expected to rise during the forecast period there by driving a significant growth of the wearable blood pressure monitor market.

Request Brochure of Report: https://www.futuremarketinsights.com/reports/brochure/rep-gb-9401

Wearable blood pressure monitor Market: Regional Outlook

North America and Europe take the maximum share of the Wearable blood pressure monitor market. Increased adoption of advance technology, rise in healthcare spending, and increase in awareness in these regions are some of the factors that drive the growth of the Wearable blood pressure monitor market. However Asia Pacific region is expected to have the a significantly high growth rate due to increasing aging population, rise in hypertension patient pool in the region and need for continuous or periodic monitoring of patients.

Wearable blood pressure monitor Market: Key Players

Some of the Key players in the Wearable blood pressure monitor market include, Blipcare, iHealth Labs Inc., OMRON Corporation, Koninklijke Philips N.V., Pyle Audio, ForaCare Suisse AG, Qardio, Inc., Xiaomi, Medaval Ltd., Nokia Corporation, Koogeek Inc., and Inventum Huishoudelijke Apparaten B.V., among many others.

Feel free to ask your queries at https://www.futuremarketinsights.com/ask-question/rep-gb-9401

Wearable blood pressure monitor Market: Segmentation

The global Wearable blood pressure monitor market is segmented by product type, indication, end users and region:

According to a recent study by Future Market Insights (FMI), sales of infection prevention products are expected to top US$ 37.4 Bn in 2021, at a CAGR of over 4.2% during the forecast period (2021-2031).